Explanipedia

Viremia Does Not Independently Predict Cardiovascular Disease in People With HIV: A RESPOND Cohort Study Open

Olof Elvstam, Lene Ryom, Bastian Neesgaard, Luba Tau, Huldrych F. Günthard , et al. · 2025

Background HIV viremia has been considered a cardiovascular disease (CVD) risk factor, but many studies have had insufficient data on potential confounders. We explored the association between viremia and CVD after adjusting for establishe…

Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus Open

Frédérique Chammartin, Amanda Mocroft, Alexander Egle, Robert Zangerle, Colette Smith , et al. · 2023

Background Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prog…

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV Open

Lauren Greenberg, Lene Ryom, Elżbieta Bąkowska, Ferdinand Wit, Heiner C. Bucher , et al. · 2023

Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 20…

Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015–2020 Open

Lia Gvinjilia, Davit Baliashvili, Shaun Shadaker, Francisco Averhoff, Levan Kandelaki , et al. · 2023

Background Mortality related to hepatitis C virus (HCV) infection is a key indicator for elimination. We assessed the impact of HCV infection and treatment on mortality in the country of Georgia during 2015–2020. Methods We conducted a pop…

Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study Open

Hortensia Álvarez, Amanda Mocroft, Lene Ryom, Bastian Neesgaard, Simon Edwards , et al. · 2023

Background There are conflicting data regarding baseline determinants of virological nonsuppression outcomes in persons with human immunodeficiency virus (HIV) starting antiretroviral treatment (ART). We evaluated the impact of different b…

Effect of remdesivir on mortality and the need for mechanical ventilation among hospitalized patients with COVID-19: real-world data from a resource-limited country Open

Revaz Metchurtchlishvili, Nikoloz Chkhartishvili, Akaki Abutidze, Marina Endeladze, Marine Ezugbaia , et al. · 2023

Treatment of hepatitis C in primary health care in the country of Georgia Open

E Dolmazashvili, Lali Sharvadze, Akaki Abutidze, Nikoloz Chkhartishvili, Manana Todua , et al. · 2022

Content available: Audio Recording.

The prevalence of hyperglycemia and its impact on mortality among people living with HIV in Georgia Open

Tea Borkowska, Nikoloz Chkhartishvili, Ekaterine Karkashadze, Otar Chokoshvili, Pati Gabunia , et al. · 2022

Background Life expectancy and quality of life of people living with HIV have been dramatically improved after introducing antiretroviral therapy, and the prevalence of non-communicable diseases has increased. Several studies have found th…

HIV Glasgow, 23–26 October 2022, Glasgow, UK / Virtual Open

Miłosz Parczewski, Elżbieta Jabłonowska, Kamila Wójcik, D. H. Zhyvytsia, Magdalena Witak‐Jêdra , et al. · 2022

Background: Treatment failures to modern ART regimens are of concern, as they might limit future drug options leading to clinical failure. Real-world estimates of the rate of multiple failures to modern regimens are lacking and long-term c…

Molecular Epidemiology of HIV-1 in Eastern Europe and Russia Open

Maarten van de Klundert, Anastasiia Antonova, Giulia Di Teodoro, Rafael Ceña-Díez, Nikoloz Chkhartishvili , et al. · 2022

The HIV epidemic in Eastern Europe and Russia is large and not well-controlled. To describe the more recent molecular epidemiology of HIV-1, transmitted drug resistance, and the relationship between the epidemics in this region, we sequenc…

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct‐acting antivirals—Results from the EuroSIDA study Open

Myroslava Nikolaichuk, Amanda Mocroft, Gilles Wandeler, János Szlávik, Magnús Gottfreðsson , et al. · 2022

Objectives Our objective was to determine whether antiretroviral drugs (ARVs) were used according to the European AIDS Clinical Society (EACS) guidelines for people with HIV/hepatitis C virus (HCV) coinfection treated with direct‐acting an…

Observational cohort study of rilpivirine (RPV) utilization in Europe Open

Alessandro Cozzi‐Lepri, Lars Peters, Annegret Pelchen–Matthews, Bastian Neesgaard, Stéphane De Wit , et al. · 2022

The prevalence of Type 2 Diabetes among people living with HIV in Georgia Open

Tea Borkowska, Ekaterine Karkashadze, Nikoloz Chkhartishvili, Otar Chokoshvili, Tengiz Tsertsvadze · 2022

The number of people living with human immunodeficiency virus (HIV) is increasing due to improved screening, faster diagnosis, newer methods, availability and acceptance of treatment, but the prevalence of non-communicable diseases, partic…

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting Open

Lauren Greenberg, Lene Ryom, Bastian Neesgaard, José M. Miró, Line Dahlerup Rasmussen , et al. · 2022

Background Limited data exist examining the association between incident cancer and cumulative integrase inhibitor (INSTI) exposure. Methods Participants were followed from baseline (latest of local cohort enrollment or January 1, 2012) un…

HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe Open

Sarah Amele, Anastasia Karachalia Sandri, Alison Rodger, Linos Vandekerckhove, Thomas Benfield , et al. · 2021

Objectives Although direct‐acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV‐coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained v…

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium Open

Loveleen Bansi‐Matharu, Andrew Phillips, Cristiana Oprea, Katharina Grabmeier‐Pfistershammer, Huldrych F. Günthard , et al. · 2021

Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps Open

Christian Kraef, Adrian Bentzon, Alena Skrahina, Amanda Mocroft, Lars Peters , et al. · 2021

Objectives In some eastern European countries, serious challenges exist to meet the HIV‐, tuberculosis (TB)‐ and hepatitis‐related target of the United Nations Sustainable Development Goals. Some of the highest incidence rates for HIV and …

Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus Open

Lauren Greenberg, Lene Ryom, Bastian Neesgaard, Gilles Wandeler, Thérèse Staub , et al. · 2020

Background Limited data exist that compare clinical outcomes of 2-drug regimens (2DRs) and 3-drug regimens (3DRs) in people living with human immunodeficiency virus. Methods Antiretroviral treatment–experienced individuals in the Internati…

Characteristics and outcomes of hospitalized adult COVID-19 patients in Georgia Open

Tengiz Tsertsvadze, Marina Ezugbaia, Marina Endeladze, L Ratiani, Neli Javakhishvili , et al. · 2020

Objective Describe presenting characteristics of hospitalized patients and explore factors associated with in-hospital mortality during the first wave of pandemic in Georgia. Methods This retrospective study included 582 adult patients adm…

Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons Open

Amanda Mocroft, Jens Lundgren, Juergen Rockstroh, Inka Aho, Gilles Wandeler , et al. · 2020

Background The role of hepatitis C virus (HCV) coinfection and HCV-RNA in the development of diabetes mellitus (DM) in HIV-positive persons remains unclear. Methods Poisson regression was used to compare incidence rates of DM (blood glucos…

SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia Open

Tengiz Tsertsvadze, Lana Gatserelia, Marine Mirziashvili, Natia Dvali, Akaki Abutidze , et al. · 2020

Background Georgia timely implemented effective response measures, with testing, contact tracing and isolation being the main pillar of the national response, achieving the lowest cumulative incidence of SARS-CoV-2 in the European region. …

CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies Open

Fabienne Caby, Marguerite Guiguet, Laurence Weiss, Alan Winston, Jose M Miró , et al. · 2020

Background A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral…

The impact on mortality of a national hepatitis C elimination program, Georgia, 2015–2019 Open

Lia Gvinjilia, Shaun Shadaker, Amiran Gamkrelidze, Tengiz Tsertsvadze, Nikoloz Chkhartishvili , et al. · 2020

Management of hepatitis C in primary healthcare in the country of Georgia Open

Tengiz Tsertsvadze, Akaki Abutidze, Lali Sharvadze, Nikoloz Chkhartishvili, Amiran Gamkrelidze , et al. · 2020

Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2019 Open

Tengiz Tsertsvadze, Amiran Gamkrelidze, Nikoloz Chkhartishvili, Akaki Abutidze, Lali Sharvadze , et al. · 2020

Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral‐naïve persons starting treatment Open

Amanda Mocroft, B. Neesgard, Robert Zangerle, Armin Rieger, Antonella Castagna , et al. · 2020

Objectives Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real‐world settings are limited…

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE Open

Andrew Atkinson, Marcel Zwahlen, Diana Barger, Antonella d’Arminio Monforte, Christoph Stephan , et al. · 2020

Background Using data from the COHERE collaboration, we investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all patients on antiretroviral therapy (ART) with suppressed plasma human immunodeficien…

HIV care in times of the COVID-19 crisis — Where are we now in Central and Eastern Europe? Open

Justyna Kowalska, Agata Skrzat‐Klapaczyńska, Dominik Bursa, Tatevik Balayan, Josip Begovać , et al. · 2020

A shortage of resources is evident, with an impact on HIV care inevitable. We need to prepare to operate with minimal medical resources, with the aim of securing constant supplies of ART. Non-governmental organizations should re-evaluate t…

Uptake and outcomes of generic dolutegravir based antiretroviral therapy in Georgia Open

Nikoloz Chkhartishvili, Nino Rukhadze, Lali Sharavdze, Pati Gabuni, N Bolokadze , et al. · 2020

Background : In July 2018 the World Health Organization updated antiretroviral therapy guidelines to recommend dolutegravir (DTG) as preferred first line drug. DTG was introduced in Georgia in 2017 and since 2018 has been prescribed as pre…

Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia Open

Tengiz Tsertsvadze, Amiran Gamkrelidze, Muazzam Nasrullah, Lali Sharvadze, Juliette Morgan , et al. · 2020

Nikoloz Chkhartishvili YOU? Author Swipe